Compare Stocks: APRE, MDXH, RADX, and QNCX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$0.81 -4.0%	$0.71	$0.55 ▼ $1.69	$10.14M	1.52	999,836 shs	397,910 shs
MDXH MDxHealth	$0.73 +1.0%	$0.52	$0.40 ▼ $5.33	$36.04M	1.42	2.52 million shs	173,285 shs
QNCX Quince Therapeutics	$32.17 -4.7%	$23.84	$15.10 ▼ $909.98	$32.72M	1.36	222,735 shs	29,562 shs
RADX Radiopharm Theranostics	$2.29 -5.0%	$3.51	$2.04 ▼ $16.25	$33.11M	1.63	100,633 shs	39,525 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	0.00%	+30.97%	+35.26%	+2.78%	-46.42%
MDXH MDxHealth	0.00%	-3.01%	+72.42%	+9.16%	-79.70%
QNCX Quince Therapeutics	0.00%	-0.53%	+44.29%	+52.03%	-89.45%
RADX Radiopharm Theranostics	0.00%	-1.23%	-23.49%	-48.50%	-56.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$0.81 -4.0%	$0.71	$0.55 ▼ $1.69	$10.14M	1.52	999,836 shs	397,910 shs
MDXH MDxHealth	$0.73 +1.0%	$0.52	$0.40 ▼ $5.33	$36.04M	1.42	2.52 million shs	173,285 shs
QNCX Quince Therapeutics	$32.17 -4.7%	$23.84	$15.10 ▼ $909.98	$32.72M	1.36	222,735 shs	29,562 shs
RADX Radiopharm Theranostics	$2.29 -5.0%	$3.51	$2.04 ▼ $16.25	$33.11M	1.63	100,633 shs	39,525 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	0.00%	+30.97%	+35.26%	+2.78%	-46.42%
MDXH MDxHealth	0.00%	-3.01%	+72.42%	+9.16%	-79.70%
QNCX Quince Therapeutics	0.00%	-0.53%	+44.29%	+52.03%	-89.45%
RADX Radiopharm Theranostics	0.00%	-1.23%	-23.49%	-48.50%	-56.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	2.40	Hold	$3.07	280.91% Upside
MDXH MDxHealth	2.40	Hold	$2.17	197.58% Upside
QNCX Quince Therapeutics	2.42	Hold	$260.00	708.21% Upside
RADX Radiopharm Theranostics	2.33	Hold	$11.00	380.35% Upside

Current Analyst Ratings Breakdown

Latest APRE, MDXH, RADX, and QNCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/26/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $2.00
8/20/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$68.00
8/18/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$70.00
8/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$5.00 ➝ $3.00
8/13/2026	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$3.00
8/12/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00
7/17/2026	APRE Aprea Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$290K	34.95	N/A	N/A	$1.52 per share	0.53
MDXH MDxHealth	$114.02M	0.32	N/A	N/A	($0.24) per share	-3.03
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A
RADX Radiopharm Theranostics	$2.35M	14.09	N/A	N/A	$3.52 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.60M	-$1.08	N/A	N/A	N/A	-4,405.59%	-47.60%	-40.97%	11/11/2026 (Estimated)
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)
RADX Radiopharm Theranostics	-$24.83M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest APRE, MDXH, RADX, and QNCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/12/2026	Q2 2026	APRE Aprea Therapeutics	-$0.1775	-$0.07	+$0.1075	-$0.07	$0.25 million	N/A
7/31/2026	Q4 2026	RADX Radiopharm Theranostics	N/A	-$0.81	N/A	-$0.8050	N/A	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
RADX Radiopharm Theranostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	13.56	13.56
MDXH MDxHealth	N/A	1.15	0.98
QNCX Quince Therapeutics	N/A	14.52	14.52
RADX Radiopharm Theranostics	N/A	3.01	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
MDXH MDxHealth	N/A
QNCX Quince Therapeutics	30.75%
RADX Radiopharm Theranostics	N/A

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	10.49%
MDXH MDxHealth	1.70%
QNCX Quince Therapeutics	7.10%
RADX Radiopharm Theranostics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	12.59 million	11.27 million	No Data
MDXH MDxHealth	300	49.50 million	48.66 million	Not Optionable
QNCX Quince Therapeutics	60	1.02 million	960,000	Optionable
RADX Radiopharm Theranostics	N/A	14.46 million	N/A	N/A

APRE, MDXH, RADX, and QNCX Headlines

Recent News About These Companies

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

August 26, 2026 | globenewswire.com

Radiopharm Theranostics (NASDAQ:RADX) Stock Price Down 8.4% - Here's Why

August 21, 2026 | americanbankingnews.com

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

August 20, 2026 | globenewswire.com

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

August 17, 2026 | finance.yahoo.com

RADX: RAD101 Topline & FY:26 Cash Flows

August 3, 2026 | finance.yahoo.com

Radiopharm Dips on Securities Pact

July 25, 2026 | baystreet.ca

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

July 24, 2026 | globenewswire.com

Radiopharm Highlights Data Release

July 23, 2026 | baystreet.ca

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

July 22, 2026 | globenewswire.com

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

July 22, 2026 | globenewswire.com

Radiopharm Theranostics Ltd ADR RADX

July 16, 2026 | morningstar.comM

Radiopharm Theranostics Limited Sponsored ADR

May 14, 2026 | cnn.com

RADX: Fiscal 3Q:26 Cash Flow Report

May 13, 2026 | finance.yahoo.com

Radiopharm Theranostics Ltd. ADR

May 13, 2026 | barrons.com

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

April 28, 2026 | insidermonkey.com

Radiopharm Theranostics Reports Business Update

April 23, 2026 | globenewswire.com

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer ...

April 20, 2026 | finance.yahoo.com

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

April 16, 2026 | markets.businessinsider.com

Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26

April 16, 2026 | msn.com

Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60

April 9, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, MDXH, RADX, and QNCX Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$0.81 -0.03 (-3.99%)

As of 02:20 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

MDxHealth NASDAQ:MDXH

$0.73 +0.01 (+1.03%)

As of 02:20 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Quince Therapeutics NASDAQ:QNCX

$32.17 -1.58 (-4.68%)

As of 02:21 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Radiopharm Theranostics NASDAQ:RADX

$2.29 -0.12 (-4.98%)

As of 02:17 PM Eastern

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APRE, MDXH, RADX, and QNCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APRE, MDXH, RADX, and QNCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APRE, MDXH, RADX, and QNCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, MDXH, RADX, and QNCX Company Descriptions

Aprea Therapeutics NASDAQ:APRE

MDxHealth NASDAQ:MDXH

Quince Therapeutics NASDAQ:QNCX

Radiopharm Theranostics NASDAQ:RADX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APRE, MDXH, RADX, and QNCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APRE, MDXH, RADX, and QNCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APRE, MDXH, RADX, and QNCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, MDXH, RADX, and QNCX Company Descriptions

Aprea Therapeutics NASDAQ:APRE

MDxHealth NASDAQ:MDXH

Quince Therapeutics NASDAQ:QNCX

Radiopharm Theranostics NASDAQ:RADX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools